NIMENRIX (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Indications And Clinical Use

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

NIMENRIX is indicated for the active immunization of individuals from 6 weeks to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y.